Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756924 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
A Phase 2 study, sponsored by Arrevus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01756924: Clinical Trial Phase 2 study, sponsored by Arrevus.
NCT01756924 is a Phase 2 study that was terminated before completion, run by Arrevus. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756924, a Phase 2 study, was terminated before completion, sponsored by Arrevus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
Interventions
- DRUG Rifampin
- DRUG CEM-102
- DRUG IV or Oral standard of care antibiotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756924
The ClinicalTrials.gov registry entry for NCT01756924 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrevus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT01756924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756924 about?
NCT01756924 is a clinical study titled "Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection". To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
What is the current status of trial NCT01756924?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01756924?
The interventions under investigation include: Rifampin (DRUG), CEM-102 (DRUG), IV or Oral standard of care antibiotics (DRUG).
Who is sponsoring clinical trial NCT01756924?
This trial is sponsored by Arrevus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.